Skip to main content

Limb-Girdle Muscular Dystrophy Type 2E

  • Chapter
  • First Online:
Genetic Neuromuscular Disorders
  • 156 Accesses

Abstract

This disorder has been recognized to be due to mutations in the SGCB gene encoding the beta-sarcoglycan protein subunit, which results in biochemical deficiency of the entire sarcoglycan protein complex. This primary defect gives rise to a severe clinical phenotype of muscular dystrophy, which is usually associated with severe dilated cardiomyopathy. While alpha- and gamma-sarcoglycan proteins are expressed almost exclusively in striated muscle, beta- and delta-sarcoglycans are expressed additionally in smooth muscle and coronary vessels, suggesting that in primary beta- and delta-sarcoglycanopathies, a dysfunction of vascular function and nNOS activity may be involved in the pathogenesis of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bönnemann CG, Modi R, Noguchi S, et al. Beta-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nat Genet. 1995;11(3):266–73.

    Article  PubMed  Google Scholar 

  2. Duggan DJ, Gorospe JRM, Fanin M, Hoffman EP, Angelini C. Mutations in the sarcoglycan genes in patients with myopathy. N Engl J Med. 1997;336:618–24.

    Article  CAS  PubMed  Google Scholar 

  3. Melacini P, Fanin M, Duggan DJ, et al. Heart involvement in muscular dystrophies due to sarcoglycan gene mutations. Muscle Nerve. 1999;22:473–9.

    Article  CAS  PubMed  Google Scholar 

  4. Fanin M, Melacini P, Boito C, Pegoraro E, Angelini C. LGMD2E patients risk developing dilated cardiomyopathy. Neuromuscul Disord. 2003;13:303–9.

    Article  CAS  PubMed  Google Scholar 

  5. Fanin M, Tasca E, Nascimbeni AC, Angelini C. Sarcolemmal nNOS defect in LGMD: an adverse modulating factor in the course of disease? J Neuropathol Exp Neurol. 2009;68:383–90.

    Article  CAS  PubMed  Google Scholar 

  6. Pegoraro E, Fanin M, Angelini C, Hoffman EP. Prenatal diagnosis in a family affected with beta-sarcoglycan muscular dystrophy. Neuromuscul Disord. 1999;9(5):323.

    Article  CAS  PubMed  Google Scholar 

  7. Fanin M, Hoffman EP, Angelini C, Pegoraro E. Private beta- and gamma-sarcoglycan gene mutations: evidence of a founder effect in northern Italy. Hum Mutat. 2000;16:13–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Angelini, C. (2018). Limb-Girdle Muscular Dystrophy Type 2E. In: Genetic Neuromuscular Disorders. Springer, Cham. https://doi.org/10.1007/978-3-319-56454-8_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56454-8_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56453-1

  • Online ISBN: 978-3-319-56454-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics